BCS class IV drugs: Highly notorious candidates for formulation development

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Biopharmaceutics

Background:

• Biopharmaceutics Classification System (BCS) Class IV drugs present significant formulation challenges due to poor aqueous solubility, low permeability, and high inter-subject variability.
• These drugs often exhibit erratic absorption and are substrates for efflux transporters like P-glycoprotein and metabolic enzymes like CYP3A4, further limiting their therapeutic potential.
• Many drug candidates in development pipelines fall into BCS Class IV, necessitating innovative delivery solutions.

Purpose of the Study:

• To review and highlight various advanced formulation techniques and emerging strategies for developing effective oral and per-oral delivery systems for BCS Class IV drugs.
• To discuss the inherent hurdles in formulating these drugs and the importance of formulation design for successful drug development.
• To identify and address the roadblocks in the clinical development and regulatory approval of these advanced drug delivery systems.

Main Methods:

• Exploration of formulation strategies including lipid-based delivery systems, polymer-based nanocarriers, and crystal engineering (nanocrystals, co-crystals).
• Investigation of liquisolid technology, self-emulsifying solid dispersions, and methods to overcome P-glycoprotein efflux.
• Analysis of challenges in scale-up, cGMP manufacturing, quality control, process validation, and regulatory guidelines.

Main Results:

• Several scalable formulation strategies exist for BCS Class IV drugs, including nanocarriers and advanced solid dosage forms.
• Techniques like lipid-based systems and crystal engineering show promise in enhancing solubility and permeability.
• Overcoming P-glycoprotein efflux and extensive pre-systemic metabolism are key targets for improved bioavailability.

Conclusions:

• Successful clinical translation of BCS Class IV drugs requires overcoming significant formulation and delivery challenges.
• Advanced formulation strategies offer viable solutions, but a deeper understanding of physical chemistry is needed to move beyond trial-and-error development.
• Addressing scale-up, manufacturing, and regulatory hurdles is crucial for bringing these improved drug delivery systems to market.